➤ For most women, early-stage ovarian cancer generates a characteristic cluster of symptoms that occurs primarily in the gastrointestinal system.
D elays in the diagnosis of ovarian cancer are a problem of international scope. Misperceptions about and misdiagnoses of the malignancy continue to contribute to late-stage tumor diagnosis for approximately 70%-75% of women with ovarian cancer ("NIH Consensus Conference," 1995; Tait, 1999) . The situation has been described as simply unacceptable in a society with modern technologies (Wikborn, Pettersson, & Moberg, 1996) . Limited research support is available for developing and testing secondary screening strategies to address diagnostic delay. Delays in diagnosis result in the minimization or loss of the opportunity to attain a survival rate of approximately 90% for women with the malignancy (Almadrones, Gordon, & Fitch, 2002) .
Signifi cant advancements regarding ovarian cancer have been made in recent decades, particularly in the identifi cation of individual risk factors and protective behaviors. The human genome has been mapped, a number of genetic mutations have been discovered, and personal and intergenerational genetic links have been identifi ed more precisely. Blood, tissue, and molecular indicators, which might serve as gauges of future malignancy development, continue to be under intense study and clinical testing. As a result of the advancements, new regimens of chemopharmacology have been developed and now are available for treatment. Clinical assessments using family histories of cancer and individual risk factors have improved predictions of risk potential. Current treatment goals focus on controlling the disease, increasing survival, and improving quality of life. Current prevention activities focus on women obtaining yearly bimanual pelvic examinations, including specialized tests, as needed, for localized and systemic disease detection; identifying individual risk factors and protective behaviors; and mapping the cancer history of families. However, none of these actions individually or collectively has proven to be effective in identifying early ovarian cancer development.
Basic research has focused on the discovery of primary prevention tests for asymptomatic women. At the same time, the development of clinically based secondary screening approaches to reduce delays in diagnosis has received less emphasis. The development of more precise knowledge regarding the early diagnosis-seeking process, the identifi cation of delays embedded in the process, and the clarifi cation of the structures and circumstances that support their continuance is needed.
